What is Orphanet-Spain's Revenue?
Orphanet-Spain's estimated revenue for 2024 is $1.01M.
What does Orphanet-Spain do?
ORPHANET was established in 1997 by the French Ministry of Health and by INSERM as a source of information concerning rare diseases (RD). Thanks to the European Commission funding, Orphanet began its activities in Spain in 2002 and, since 2008, it has been present in 38 European states and several surrounding countries. The information is available in five languages, including Spanish.
Since the beginning of 2009, the Biomedical Network Research Centre for Rare Diseases (CIBERER) and the Research Institute of the Hospital Universitari Vall d'Hebron (IR-HUVH) have co-funded Orphanet activities in Spain. Its team is composed of four scientists and two national coordinators, Dr. Francesc Palau and Dr. Miguel del Campo. This collaboration intends to consolidate Orphanet as the database that unifies all the RD resources in Spain.
Orphanet serves those communities interested in learning more about RD, in particular patients and their relatives, healthcare providers, drug companies and biotech staff, researchers and policy makers. This portal has collected information about 5,717 rare diseases, 521 orphan drugs, 1,739 RD patient organizations, 11,510 health providers and 3,292 clinics specialized in pathologies of low prevalence. With an average of 20,000 daily visitors, Orphanet's goal is to contribute to an improvement in the diagnosis, management and treatment of RD patients. This portal includes:
- RD encyclopaedia
- Directory of medical resources
- Patient organizations' directory
- Search for rare disorders by clinical signs
- Public database in orphan drugs
- RDPlatform platform (in process of developing): public database of molecules with potential orphan indications and research projects searching for funding partnership. These data are being downloaded to the next version of the Orphanet website
- Confidential registry of patients (in process of developing)
- OrphaNews Europe and France newsletters
